Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Ceribell (Nasdaq: CBLL) announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York.
The session is scheduled for Thursday, November 20, 2025 at 5:30 a.m. PST / 8:30 a.m. EST. A live and archived webcast will be available in the company's Investor Relations section at https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) ha annunciato che il direttore finanziario Scott Blumberg parteciperà a una chiacchierata informale al Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum a New York.
La sessione è prevista per giovedì 20 novembre 2025 alle 5:30 del mattino PT / 8:30 del mattino ET. Un webcast in diretta e una versione registrata saranno disponibili nella sezione Investor Relations dell'azienda all'https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) anunció que el director financiero Scott Blumberg participará en una charla junto a la chimenea en el Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum en Nueva York.
La sesión está programada para jueves 20 de noviembre de 2025 a las 5:30 a.m. PT / 8:30 a.m. ET. Una transmisión en vivo y su archivo estarán disponibles en la sección de Investor Relations de la empresa en https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL)는 최고재무책임자 Scott Blumberg가 뉴욕에서 열리는 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum에서 fireside chat에 참여한다고 발표했습니다.
세션은 2025년 11월 20일 목요일 오전 5시 30분 PT / 오전 8시 30분 ET에 예정되어 있습니다. 생방송 및 보관용 웹캐스트는 회사의 IR(Investor Relations) 섹션에서 https://investors.ceribell.com/로 제공됩니다.
Ceribell (Nasdaq: CBLL) a annoncé que le directeur financier Scott Blumberg participera à une discussion informelle lors du Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum à New York.
La session est prévue pour jeudi 20 novembre 2025 à 5 h 30, heure du Pacifique / 8 h 30, heure de l’Est. Une diffusion en direct et sa version enregistrée seront disponibles dans la section Investor Relations de l’entreprise à l’adresse https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) kündigte an, dass Finanzvorstand Scott Blumberg an einem Fireside-Chat beim Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York teilnehmen wird.
Die Sitzung ist für Donnerstag, 20. November 2025 um 5:30 Uhr PT / 8:30 Uhr ET geplant. Live- und archivierte Webcasts stehen im Bereich Investor Relations des Unternehmens unter https://investors.ceribell.com/ zur Verfügung.
Ceribell (Nasdaq: CBLL) أعلنت أن المدير المالي سكوت بلومبرغ سيشارك في دردشة Fireside في منتدى Canaccord Genuity MedTech, Diagnostics and Digital Health & Services في نيويورك.
من المقرر عقد الجلسة في الخميس 20 نوفمبر 2025 الساعة 5:30 صباحاً بتوقيت المحيط الهادئ / 8:30 صباحاً بتوقيت شرق الولايات المتحدة. ستكون هناك بث مباشر ومتابعة مسجلة متاحة في قسم علاقات المستثمرين في الشركة على https://investors.ceribell.com/.
- None.
- None.
SUNNYVALE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The fireside chat will take place on Thursday, November 20, 2025, at 5:30 a.m. Pacific Standard Time / 8:30 a.m. Eastern Standard Time.
Event: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Date: Thursday, November 20, 2025
Time: 5:30 a.m. PST / 8:30 a.m. EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detecting suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Brian Price
Press@ceribell.com
FAQ
When will Ceribell CFO Scott Blumberg speak at the Canaccord Genuity forum (CBLL)?
How can investors watch Ceribell (CBLL) at the Canaccord Genuity MedTech forum?
What topics will Ceribell (CBLL) cover at the Canaccord Genuity MedTech forum?
Who is representing Ceribell (CBLL) at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum?
Where is the Canaccord Genuity MedTech forum where Ceribell (CBLL) will appear?
Will the Ceribell (CBLL) fireside chat be available after November 20, 2025?
